Effect of Psychoeducational Intervention on Donepezil Retention Rate and Analysis of Reasons for the Discontinuation in Patients with Alzheimer’s Dementia: A Randomized Study

References

• Kamaradova D, Latalova K, Prasko J, et al. Connection between self-stigma, adherence to treatment, and discontinuation of medication. Patient Prefer Adherence. 2016;10:1289–1298. doi:10.2147/PPA.S99136
   PubMed Web of Science ®Google Scholar
• Ong AD, Uchino BN, Wethington E. Loneliness and health in older adults: a mini-review and synthesis. Gerontology. 2016;62(4):443–449. doi:10.1159/000441651
   PubMed Web of Science ®Google Scholar
• Homma A, Imai Y, Tago H, et al. Long-term safety and efficacy of donepezil in patients with severe Alzheimer’s disease: results from a 52-week, open-label, multicenter, extension study in Japan. Dement Geriatr Cogn Disord. 2009;27(3):232–239. doi:10.1159/000203887
   Web of Science ®Google Scholar
• Arlt S, Lindner R, Rösler A, von Renteln-kruse W. Adherence to medication in patients with dementia: predictors and strategies for improvement. Drugs Aging. 2008;25(12):1033–1047. doi:10.2165/0002512-200825120-00005
   PubMed Web of Science ®Google Scholar
• El-Saifi N, Moyle W, Jones C, Tuffaha H. Medication adherence in older patients with dementia: a systematic literature review. J Pharm Pract. 2018;31(3):322–334. doi:10.1177/0897190017710524
   Web of Science ®Google Scholar
• Gardette V, Lapeyre-Mestre M, Piau A, et al. A 2-year prospective cohort study of antidementia drug non-persistency in mild-to-moderate Alzheimer’s disease in Europe: predictors of discontinuation and switch in the ICTUS study. CNS Drugs. 2014;28(2):157–170. doi:10.1007/s40263-013-0133-3
   Web of Science ®Google Scholar
• O’Regan J, Lanctôt KL, Mazereeuw G, Herrmann N. Cholinesterase inhibitor discontinuation in patients with Alzheimer’s disease: a meta-analysis of randomized controlled trials. J Clin Psychiatry. 2015;76(11):e1424–e1431. doi:10.4088/JCP.14r09237
   PubMed Web of Science ®Google Scholar
• Xingyan Y, Weihua Y, Wenkai Y, Yang L. Usage and adherence of antidementia drugs in a memory clinic cohort in Chongqing, Southwest China. Psychogeriatrics. 2020;20(5):706–712. doi:10.1111/psyg.12568
   Web of Science ®Google Scholar
• Knapp M, King D, Romeo R, et al. Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer’s disease (the DOMINO-AD trial). Int J Geriatr Psychiatry. 2017;32(12):1205–1216. doi:10.1002/gps.4583
   Web of Science ®Google Scholar
• Kobayashi H, Arai H. Donepezil may reduce the risk of comorbidities in patients with Alzheimer’s disease: a large-scale matched case-control analysis in Japan. Alzheimers Dement. 2018;4(1):130–136. doi:10.1016/j.trci.2018.03.002
   Google Scholar
• Nordström P, Religa D, Wimo A, Winblad B, Eriksdotter M. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer’s disease. Eur Heart J. 2013;34(33):2585–2591. doi:10.1093/eurheartj/eht182
   PubMed Web of Science ®Google Scholar
• Shikimoto R, Sado M, Mimura M. [The social costs of dementia in Japan: focusing on the informal care cost]. Brain Nerve. 2016;68(8):939–944. Japanese.
   Google Scholar
• Nakanishi M, Igarashi A, Ueda K, et al. Costs and resource use of community-dwelling patients with Alzheimer’s disease in Japan: 18-month results from the GERAS-J study. Curr Med Res Opin. 2021;37(8):1331–1339. doi:10.1080/03007995.2021.1922369
   PubMed Web of Science ®Google Scholar
• Watanabe N, Yamamura K, Suzuki Y, et al. Pharmacist-based donepezil outpatient consultation service to improve medication persistence. Patient Prefer Adherence. 2012;6:605–611.
   Web of Science ®Google Scholar
• Kroger E, Tatar O, Vedel I, et al. Improving medication adherence among community-dwelling seniors with cognitive impairment: a systematic review of interventions. Int J Clin Pharm. 2017;39(4):641–656. doi:10.1007/s11096-017-0487-6
   Web of Science ®Google Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th Text Revision Edition. Washington DC: American Psychiatric Association; 2000.
   Google Scholar
• Honma A. [Alzheimer’s disease patients ADL respect of donepezil hydrochloride effective and discontinuations prognosis (Aricept special survey)]. Geriatr Med. 2009;47(8):1047–1059. Japanese.
   Google Scholar
• Honma A. [Advanced Alzheimer’s disease donepezil hydrochloride for 10 mg/safety and efficacy of daily administration (Aricept (R) specific-use results surveys)]. Geriatr Med. 2013;51(3):309–342. Japanese.
   Google Scholar
• Ndukwe HC, Nishtala PS. Donepezil adherence, persistence and time to first discontinuation in a three-year follow-up of older people. Dement Geriatr Cogn Dis Extra. 2015;5(3):482–491. doi:10.1159/000441894
   PubMed Web of Science ®Google Scholar
• Umegaki H, Itoh A, Suzuki Y, Nabeshima T. Discontinuation of donepezil for the treatment of Alzheimer’s disease in geriatric practice. Int Psychogeriatr. 2008;20(4):800–806. doi:10.1017/S1041610208007011
   Web of Science ®Google Scholar
• Van der Stigchel S, de Bresser J, Heinen R, et al. Parietal involvement in constructional apraxia as measured using the pentagon copying task. Dement Geriatr Cogn Disord. 2018;46(1–2):50–59. doi:10.1159/000491634
   Web of Science ®Google Scholar
• Makuuchi M, Kaminaga T, Sugishita M. Both parietal lobes are involved in drawing: a functional MRI study and implications for constructional apraxia. Brain Res Cogn Brain Res. 2003;16(3):338–347. doi:10.1016/S0926-6410(02)00302-6
   PubMedGoogle Scholar
• Russell C, Deidda C, Malhotra P, Crinion JT, Merola S, Husain M. A deficit of spatial remapping in constructional apraxia after right-hemisphere stroke. Brain. 2010;133(4):1239–1251. doi:10.1093/brain/awq052
   PubMed Web of Science ®Google Scholar
• Ungerleider LG, Haxby JV. ‘What’ and ‘where’ in the human brain. Curr Opin Neurobiol. 1994;4(2):157–165. doi:10.1016/0959-4388(94)90066-3
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, DSM-V 5th Edition. Washington DC: American Psychiatric Association; 2014.
   Google Scholar
• Thiruchselvam T, Naglie G, Moineddin R, et al. Risk factors for medication nonadherence in older adults with cognitive impairment who live alone. Int J Geriatr Psychiatry. 2012;27(12):1275–1282. doi:10.1002/gps.3778
   PubMed Web of Science ®Google Scholar
• Kim HJ, Shim YS, Park KH, et al. Impact of an education program for caregivers of patients with Alzheimer’s disease on treatment discontinuation and compliance in Korea. J Clin Neurol. 2021;17(3):368–375. doi:10.3988/jcn.2021.17.3.368
   Web of Science ®Google Scholar
• Geldmacher DS. Treatment guidelines for Alzheimer’s disease: redefining perceptions in primary care. Prim Care Companion J Clin Psychiatry. 2007;9(2):113–121. doi:10.4088/PCC.v09n0205
   Google Scholar
• Suzuki H, Nakata T. [Questionnaire survey on burden of medication assistance to caregiver]. Jpn J Soc Pharm. 2013;32(2):48–53. Japanese.
   Google Scholar